Products for Research Use Only
RegisterLogin

WJ35435

CAT: 0804-HY-117688Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-117688Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
WJ35435 is a dual-targeted anticancer hybrid that induces anti-HDAC (in particular HDAC1 and HDAC6) and anti-topoisomerase I activities that causes DNA damage associated with a low DNA repair capability and induces cell cycle arrest at G1- and G2-phase to apoptosis. WJ35435 induces histone H3 acetylation and phosphorylation, α-tubulin acetylation and γ-H2AX formation to achieve anti-HDAC effect. WJ35435 is promising for research of cancer[1].
CAS Number
1620054-84-3
UNSPSC
12352005
Target
Apoptosis; HDAC; Topoisomerase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wj35435.html
Smiles
O=C(C1=CC=CC2=CC3=C(N=C21)C=CC=C3)NCCCCCC(NO)=O
Molecular Formula
C20H21N3O3
Molecular Weight
351.40
References & Citations
[1]Yu C C, et al. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I[J]. Biochemical pharmacology, 2014, 90 (3) : 320-330.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
T24036-01WJ35435

Popular Products